|
Meta-IQ is an Aarhus based Danish family company that is dedicated to the development of medicine for the treatment of neurological diseases.
Dr. John D. Nieland and M.Sc. Jette G.K. Nieland are the founders of Meta-IQ. Jette is the CEO of Meta-IQ. She has international experience as a clinical and business psychologist. Jette has her M.Sc. in psychology from the University of Aarhus. John is the COO of Meta-IQ. He has an international experience in biotech and pharma and he has a Ph.D. in medicine from the Free University in Amsterdam medical faculty.
The scientific basis for the development of medicine is, as symbolized by the Meta-IQ logo, that diseases develop due to an imbalance in the immunological, psychological and metabolic state of a person which is placed upon the genetic foundation for every individual. For an indept explanation see the explanation of the Logo.
Meta-IQ develops products for:
- Alzheimer
- Depression
- Multiple Sclerosis
- Schizophrenia
- Brain tumors
The Meta-IQ drug has shown to be able to restore neuronal functioning and therefore is the first drug that has the potential to treat diseases like Alzheimer, Depression Multiple Sclerosis and Schizophrenia. These diseases are marked by a gradual decreases in neuronal signaling thereby in time induce memory or mobility loss.
The first drug to be developed is:
M-IQ 003 for the treatment of Multiple Sclerosis
In September 2011, the group of Manchester of the University of California in San Diego confirmed the data of Meta-IQ in Multiple Sclerosis. Dr. Marianne Manchester confirmed that Meta-IQs drug restores the myelin sheet that protects the individual neurons, and thereby cures the laming of the muslces in mice. see article.
To learn more about Meta-IQ see presentation: |
Management
